Elanco Animal Health Incorporated (NYSE:ELAN) Given Consensus Rating of "Moderate Buy" by Analysts

Elanco Animal Health Incorporated (NYSE:ELAN - Get Free Report) has earned a consensus rating of "Moderate Buy" from the seven ratings firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $16.71.

Several research firms have commented on ELAN. Morgan Stanley upped their price objective on shares of Elanco Animal Health from $16.00 to $17.00 and gave the company an "overweight" rating in a report on Tuesday, February 27th. The Goldman Sachs Group upped their price target on shares of Elanco Animal Health from $12.50 to $14.00 and gave the company a "sell" rating in a research note on Tuesday, February 27th. TheStreet upgraded shares of Elanco Animal Health from a "d+" rating to a "c-" rating in a research note on Friday, February 23rd. Finally, Barclays increased their target price on Elanco Animal Health from $18.00 to $19.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 27th.

Insider Transactions at Elanco Animal Health

In other news, Director R David Hoover purchased 20,000 shares of the stock in a transaction on Wednesday, March 6th. The shares were acquired at an average price of $16.14 per share, for a total transaction of $322,800.00. Following the completion of the transaction, the director now directly owns 185,000 shares of the company's stock, valued at approximately $2,985,900. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 0.57% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Jones Financial Companies Lllp bought a new stake in shares of Elanco Animal Health in the 4th quarter worth approximately $37,000. Tower Research Capital LLC TRC lifted its stake in Elanco Animal Health by 169.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,212 shares of the company's stock worth $93,000 after acquiring an additional 3,906 shares during the period. Acadian Asset Management LLC bought a new stake in Elanco Animal Health in the third quarter valued at $95,000. Capstone Investment Advisors LLC purchased a new position in Elanco Animal Health during the 1st quarter valued at $167,000. Finally, HBK Sorce Advisory LLC bought a new position in Elanco Animal Health in the 4th quarter worth $169,000. Hedge funds and other institutional investors own 97.48% of the company's stock.

Elanco Animal Health Stock Performance

ELAN stock traded up $0.06 during mid-day trading on Friday, hitting $13.53. The company had a trading volume of 3,719,972 shares, compared to its average volume of 4,351,298. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.35 and a current ratio of 2.75. The firm has a market cap of $6.69 billion, a PE ratio of -5.41, a price-to-earnings-growth ratio of 1.42 and a beta of 1.34. Elanco Animal Health has a 12 month low of $7.88 and a 12 month high of $16.88. The stock's fifty day moving average price is $15.08 and its two-hundred day moving average price is $13.96.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its quarterly earnings results on Monday, February 26th. The company reported $0.08 EPS for the quarter, missing analysts' consensus estimates of $0.10 by ($0.02). Elanco Animal Health had a positive return on equity of 6.44% and a negative net margin of 27.87%. The company had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1 billion. During the same period last year, the firm posted $0.19 EPS. The company's revenue for the quarter was up 5.1% compared to the same quarter last year. On average, analysts forecast that Elanco Animal Health will post 0.91 earnings per share for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.